Rossi Matheus Rizzato, Mazzali Marilda, de Sousa Marcos Vinicius
Renal Transplant Research Laboratory, Renal Transplant Unit, Division of Nephrology, Department of Internal Medicine, School of Medical Sciences, University of Campinas-UNICAMP, Campinas, São Paulo, Brazil.
Renal Transplant Research Laboratory, Renal Transplant Unit, Division of Nephrology, Department of Internal Medicine, School of Medical Sciences, University of Campinas-UNICAMP, Campinas, São Paulo, Brazil.
Transplant Proc. 2024 Jun;56(5):1061-1065. doi: 10.1016/j.transproceed.2024.04.021. Epub 2024 May 18.
The incidence of post-transplant diabetes mellitus (PTDM) can reach 30% during the first 6 months after kidney transplantation (KT), increasing the risk of graft failure and mortality. There is no well-established biomarker for predicting PTDM occurrence. This study evaluated the association between the abnormal 2-hour oral glucose tolerance test (OGTT) and the PTDM incidence.
A retrospective single-center study, including adult kidney transplant recipients from deceased donors, was performed between March 2021 and June 2022.
age <18 years; pretransplant diabetes mellitus (DM); death with a functioning graft; loss of follow-up and/or graft failure before 6 months post-transplant. The results of pretransplant OGTT, fasting (FPG), and afternoon plasma glucose levels at hospitalization and FPG in the first, second, and third months post-transplant were evaluated. For analysis, patients were grouped according to the PTDM diagnosis: PTDM and non-PTDM.
From 164 KT performed in the period, 50 (30%) were included, most male (n = 34, 68%), with a mean age of 48.3 ± 12.5 years. Nine patients (18%) developed PTDM, 44% between 3 and 6 months. General characteristics and immunosuppressive therapy were similar between the groups. The mean FPG in the pretransplant OGTT was significantly higher in the PTDM group compared with the non-PTDM group (85.7 ± 7.9 vs 79.1 ± 8.2, P = .03). The number of patients classified as impaired glucose tolerance (IGT) on the pre-transplant OGTT was significantly higher in the PTDM group.
IGT in the pretransplant OGTT was associated with PTDM cases in kidney transplant recipients without a previous diagnosis of DM.
肾移植(KT)后前6个月内移植后糖尿病(PTDM)的发生率可达30%,这增加了移植失败和死亡的风险。目前尚无用于预测PTDM发生的成熟生物标志物。本研究评估了2小时口服葡萄糖耐量试验(OGTT)异常与PTDM发生率之间的关联。
进行了一项回顾性单中心研究,纳入2021年3月至2022年6月期间来自已故供体的成年肾移植受者。
年龄<18岁;移植前糖尿病(DM);移植肾仍有功能时死亡;移植后6个月前失访和/或移植失败。评估了移植前OGTT、空腹血糖(FPG)、住院时下午血浆葡萄糖水平以及移植后第1、2和3个月的FPG结果。为进行分析,根据PTDM诊断将患者分组:PTDM组和非PTDM组。
在此期间进行的164例KT中,50例(30%)被纳入,大多数为男性(n = 34,68%),平均年龄为48.3±12.5岁。9例患者(18%)发生PTDM,44%发生在3至6个月之间。两组之间的一般特征和免疫抑制治疗相似。与非PTDM组相比,PTDM组移植前OGTT中的平均FPG显著更高(85.7±7.9 vs 79.1±8.2,P = 0.03)。PTDM组移植前OGTT中被分类为糖耐量受损(IGT)的患者数量显著更高。
移植前OGTT中的IGT与既往未诊断为DM的肾移植受者中的PTDM病例相关。